Cargando…
Transformation by Hras(G12V) is Consistently Associated with Mutant Allele Copy Gains and is Reversed by Farnesyl Transferase Inhibition
RAS-driven malignancies remain a major therapeutic challenge. The two-stage 7,12-dimethylbenz(a)anthracene (DMBA)/12-o-tetradecanoylphorbol-13-acetate (TPA) model of mouse skin carcinogenesis has been used to study mechanisms of epithelial tumor development by oncogenic Hras. We used mice with a Hra...
Autores principales: | Chen, Xu, Makarewicz, Jacek M., Knauf, Jeffrey A., Johnson, Linda K., Fagin, James A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025988/ https://www.ncbi.nlm.nih.gov/pubmed/24240680 http://dx.doi.org/10.1038/onc.2013.489 |
Ejemplares similares
-
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022) -
Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022) -
Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors
por: Nigam, Aradhya, et al.
Publicado: (2023) -
Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas
por: Kessler, Linda, et al.
Publicado: (2021) -
Use of Farnesyl Transferase Inhibitors in an Ageing Model in Drosophila
por: Brandt, Annely, et al.
Publicado: (2023)